These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 6364709)

  • 1. Haemodynamic and antihypertensive effect of prostacyclin.
    Szczeklik A; Gryglewski RJ; Szczeklik J; Nizankowski R
    Adv Exp Med Biol; 1984; 164():299-305. PubMed ID: 6364709
    [No Abstract]   [Full Text] [Related]  

  • 2. Epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.
    Botney M
    N Engl J Med; 1998 Jun; 338(24):1773-4. PubMed ID: 9625639
    [No Abstract]   [Full Text] [Related]  

  • 3. Integrated pharmacokinetics and pharmacodynamics of epoprostenol in healthy subjects.
    Nicolas LB; Krause A; Gutierrez MM; Dingemanse J
    Br J Clin Pharmacol; 2012 Dec; 74(6):978-89. PubMed ID: 22515646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is prostacyclin an inodilator?
    Ricksten SE
    Intensive Care Med; 2003 Sep; 29(9):1403-5. PubMed ID: 12904857
    [No Abstract]   [Full Text] [Related]  

  • 5. The effect of prostacyclin on the gastric mucosa in portal-hypertensive rats.
    Kishihara F; Hashizume M; Ohta M; Kawanaka H; Tomikawa M; Higashi H; Tanoue K; Sugimachi K
    Hepatogastroenterology; 2002; 49(43):279-84. PubMed ID: 11941975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.
    McLaughlin VV; Genthner DE; Panella MM; Rich S
    N Engl J Med; 1998 Jan; 338(5):273-7. PubMed ID: 9445406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic evaluation of continuous intravenous epoprostenol.
    Chaumais MC; Jobard M; Huertas A; Vignand-Courtin C; Humbert M; Sitbon O; Rieutord A; Montani D
    Expert Opin Drug Metab Toxicol; 2010 Dec; 6(12):1587-98. PubMed ID: 21077785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The renal haemodynamic and excretory actions of prostacyclin (PGI2) in anaesthetized dogs [proceedings].
    Hill TW; Moncada S
    Br J Pharmacol; 1978 Mar; 62(3):413P-414P. PubMed ID: 346131
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of prostacyclin on gastric mucosal RNA-content in the rat.
    Balint GA
    Exp Toxicol Pathol; 1999 May; 51(3):207-8. PubMed ID: 10334459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange.
    Schermuly RT; Roehl A; Weissmann N; Ghofrani HA; Schudt C; Tenor H; Grimminger F; Seeger W; Walmrath D
    J Pharmacol Exp Ther; 2000 Feb; 292(2):512-20. PubMed ID: 10640287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Managing patients with primary pulmonary hypertension: prostacyclin therapy.
    Albert NM; Hague K
    Am J Crit Care; 1997 Jul; 6(4):274-80. PubMed ID: 9215424
    [No Abstract]   [Full Text] [Related]  

  • 12. Systemic levels of 6-keto-prostaglandin F1 alpha following administration of inhaled aerosolized prostacyclin.
    van Heerden PV
    Anaesth Intensive Care; 1997 Dec; 25(6):701-3. PubMed ID: 9452859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haemodynamic changes induced by prostacyclin in man.
    Szczeklik J; Szczeklik A; Nizankowski R
    Br Heart J; 1980 Sep; 44(3):254-8. PubMed ID: 7000101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Additive haemodynamic effects of piroximone and prostacyclin in severe chronic heart failure.
    Albo C; Saal JP; Lellouche D; Habbal R; Benvenuti C; Deleuze P; Loisance D; Castaigne A; Dubois-Randé JL
    Eur Heart J; 1994 Apr; 15(4):528-33. PubMed ID: 8070481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An antihypertensive effect of prostacyclin.
    Sutter DM; Weeks JR
    Adv Prostaglandin Thromboxane Res; 1980; 7():789-90. PubMed ID: 6989205
    [No Abstract]   [Full Text] [Related]  

  • 16. Haemodynamic effects of a new multifactorial antihypertensive drug.
    Mancia G; Ferrari AU
    Eur Heart J; 1992 Jun; 13 Suppl A():26-9. PubMed ID: 1396848
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of severe pulmonary hypertension secondary to connective tissue diseases with continuous IV epoprostenol (prostacyclin).
    Humbert M; Sanchez O; Fartoukh M; Jagot JL; Sitbon O; Simonneau G
    Chest; 1998 Jul; 114(1 Suppl):80S-82S. PubMed ID: 9676646
    [No Abstract]   [Full Text] [Related]  

  • 18. The prostaglandins epoprostenol and iloprost increase left ventricular contractility in vivo.
    Kisch-Wedel H; Kemming G; Meisner F; Flondor M; Kuebler WM; Bruhn S; Koehler C; Zwissler B
    Intensive Care Med; 2003 Sep; 29(9):1574-83. PubMed ID: 12908096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cigarette smoking does not attenuate the cardiovascular effects of epoprostenol (prostacyclin) in humans.
    Hassan S; Macdougall IC; O'Grady J; Pickles H
    Br J Clin Pharmacol; 1982 Jul; 14(1):97-8. PubMed ID: 7049210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute hemodynamic effects of prostacyclin infusion in severe or malignant hypertension.
    Chaignon M; Tannieres-Ruffie ML; Lucsko M; Guedon J
    Eur Heart J; 1982 Oct; 3 Suppl C():39-43. PubMed ID: 6756922
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.